srch

BerGenBio Pipeline update FDA grants fast track designation Price NOK25.1 Market cap NOK2,204m NOK8.50/US$ Net cash (NOKm) at 31 March 2021 658.1 Shares in issue 87.8m Free float 61% Code BGBIO Primary exchange Oslo Secondary …

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple ...

BerGenBio Pipeline update 15 June 2021 BerGenBio (BGBIO), a pioneer in AXL biology and the development of AXL inhibitors, has two clinical-stage assets: selective tyrosine kinase inhibitor bemcentinib and functional blocking monoclonal antibody tilvestamab. FDA has granted bemcentinib fast track designation

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class drug candidates to treat aggressive cancers.

BerGenBio leverages its leadership position in understanding tumour cell plasticity to develop next generation selective inhibitors of ...

16.12.2021 · Pipeline of first-in-class AXL inhibitors for the treatment of aggressive diseases.. BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone therapy for aggressive diseases, including immune-evasive, therapy resistant cancers, fibrosis and viral infection.

Dec 16, 2021 · Pipeline of first-in-class AXL inhibitors for the treatment of aggressive diseases. BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone therapy for aggressive diseases, including immune-evasive, therapy resistant cancers, fibrosis and viral infection.

BerGenBio is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class selective AXL kinase inhibitors to treat multiple ...

Pipeline. BerGenBio is focused on developing a pipeline of transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.

Pipeline BerGenBio is focused on developing a pipeline of transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including immune-evasive, therapy resistant cancers.

Part 5 Bergenbio Patent søknader ... Part 7 BergenBio pipeline ... BerGenBio is focused on developing a pipeline of transformative drugs targeting AXL as a ...

12.09.2020 · BERGENBIO - VERDIVURDERING - ANALYSER osv 21595 Yngling ØH 01.03.2021; Forum Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 09:32: VIL PRESENTERE DATA OM COVID-BEHANDLING PÅ KONFERANSE I MARS 615 MiniMe 17.02.2021; Forum Ticker Siste Innlegg Svar Lest Av; Farma: BGBIO 12:05: Bergenbio Q4 på onsdag. iDMC 2nd update on Covid19 idag …

Subscribe to our newsletter. Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events.

Apr 13, 2018 · BerGenBio ASA is a clinical-stage biopharmaceutical company focused on developing a pipeline of first-in-class AXL kinase inhibitors as a potential cornerstone of combination cancer therapy.

BerGenBio is focused on developing a pipeline of transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, ...